» • ,

: 12
: « 33 »
:. 386-409
: 2011 .

English version

( )

. ..

- . .

, , , .

( PDF. Adobe Acrobat Reader)

1. ., .. / .: , 2008. 264 .

2. Anderson H., Deakin D.-P., Wagstaff Y. et al. A randomized study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkins disease PS IAIIB: a report from the Manchester Lymphoma Group // Br. J. Cancer. 1984. No. 6. P. 695-702.

3. Atra A., Higgs E., Capra M. et al. ChlVPP chemotherapy in children with stage IV Hodgkins disease: results of the UKCCSG HD 8201 and HD 9201 studies // Br. J. Haematol. 2002. Vol. 119. No. 3. P. 647-651.

4. Baez F., Ocampo E. Treatment of childhood Hodgkins disease with COPP-ABV (hybrid) without radiotherapy in Nicaragua // Ann. Oncol. 1997. Vol. 8. No. 3. P. 247-250.

5. Baker M.C. and Mann W.N. Hodgkins disease: a study of sixty-five cases // Guys Hosp. Rep. 1939. Vol. 89. P. 83-107.

6. Berkson J. and Gage P. Survival cures for cancer patients following treatment // J. Am. Stat. Assoc. 1952. Vol. 47. P. 501-515.

7. Boiron M., Teillet F., Bernard J. et al. A reappraisal of clinical and biological signs in staging of Hodgkins disease // Cancer Res. 1971. Vol. 31. P. 1723-1729.

8. Bonadonna G., Zucali R., Monfardini S. et al. Combination chemotherapy of Hodgkins disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP // Cancer. 1975. Vol. 36. P. 252-259.

9. Canellos G.P., Anderson J.R., Propert K.J. et al. Chemotherapy of advanced Hodgkins disease with MOPP, ABVD, or MOPP alternating with AVBD // N. Engl. J. Med. 1992. Vol. 327. P. 1478-1484.

10. Carde P. The chemotherapy/radiation balance in advanced Hodgkins lymphoma: overweight which side? // J. Clin. Oncol. 2005. Vol. 23. No. 36. P. 9058-9062.

11. De Vita V., Serpick A. Combination chemotherapy in the treatment of advanced Hodgkins disease [abstract] // Proc.Am.Assoc.Cancer Res. - 1967. V.8. P.13.

12. De Vita V., Serpick A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkins disease // Ann. Intern. Med. 1970. Vol. 73. P. 881-895.

13. Diehl V., Franklin J., Pfreundschuh M. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkins disease // N. Engl. J. Med. 2003. Vol. 348. P. 2386-2395.

14. Donaldson S.S. Pediatric Hodgkins disease up, up, and beyong // Int. J. Radiat. Oncol. Biol. Phys. 2002. Vol. 54. P. 1-8.

15. Donaldson S.S., Link M.P. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkins disease // J. Clin. Oncol. 1987. - Vol. 5. No. 5. P. 742-749.

16. Dorffel W., Luders H., Ruhl U. et al. Preliminary results of the multicenter trial GPON-HD 95 for the treatment of Hodgkins disease in children and adolescents: analysis and outlook // Clin. Pediatr. 2003. Vol. 215. P. 139-145.

17. Duggan D.B., Petroni G.R., Johnson J.L. et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkins disease: report of an Intergroup Trial // J. Clin. Oncol. 2003. Vol. 21. No. 4. P. 607-614.

18. Ekert H., Toogood I. High incidence of treatment failure with vincristine, etoposide, epirubicin, and prednisolone chemotherapy with successful salvage in childhood Hodgkin disease // Med. Pediatr. Oncol. 1999. Vol. 32. No. 4. P. 255-258.

19. Friedmann A.M., Hudson M.M., Weinstein H.J. et al. Treatment of unfavorable childhood Hodgkins disease with VEPA and low-dose, involved-field radiation // J. Clin. Oncol. 2002. Vol. 20. No. 14. P. 3088-3094.

20. Fryer C.J., Hutchinson R.J., Krailo M. et al. Efficacy ant toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkins disease in children: a report from the Childrens Cancer Study Group // J. Clin. Oncol. 1990. Vol. 8. No. 12. P. 1971-1980.

21. Fuller L.M., Gamble Y.F., Velasquez W.G. et al. Evaluation of the significance of prognostic factors in stage III Hodgkins disease treated with MOPP and radiotherapy // Cancer. 1980. Vol. 45. P. 1352-1364.

22. Gobbi P.G., Broglia C., Berte R. et al. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkins disase // Haematologica. 2000. Vol. 85. No. 7. P. 722-728.

23. Gobbi P.G., Broglia C., Levis A. et al., MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkins lymphoma: 10-year results, late toxicity and second tumors // Clin. Cancar. Res. 2006. Vol. 12. No. 2. P. 529-535.

24. Gobbi P., Levis A., Chisesi T. et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkins lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linformi // J. Clin. Oncol. 2005. Vol. 23. No. 36. P. 9198-9207.

25. Hodgkin Th. On some morbid appearences of the absorbent glands and spleen // Med. Chir. Trans. 1832. Vol. 17. P. 68-114.

26. Hoppe R.T. The contemporary management of Hodgkins disease // Radiology. 1988. Vol. 169. P. 297-304.

27. Hoppe R.T., Coleman C.N., Cox P.S. et al. The management of stage I-II Hodgkins disease with irradiation alone or combined modality therapy: the Stanford experience // Blood. 1982. Vol. 59. P. 455-465.

28. Hoppe R.T., Rosenberg S.A., Kaplan H.S. et al. Prognostic factors in pathological stage IIIA Hodgkins disease // Cancer. 1980. Vol. 46. P. 1240-1246.

29. Hudson M.M., Greenwald C., Thompson E. et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkins disease // J. Clin. Oncol. 1993. Vol. 11. No. 1. P. 100-108.

30. Hudson M.M., Krasin M., Link M.P. et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkins disease // J. Clin. Oncol. 2004. Vol. 22. No. 22. P. 4541-4550.

31. Hunger S.P., Link M.P., Donaldson S.S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkins disease: the Stanford experience // J. Clin. Oncol. 1994. Vol. 12. No. 10. P. 2160-2166.

32. Hutchinson R.J., Fryer C.J., Davis P.C. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkins disease in children: results of the Childrens Cancer Group. Phase III trial // J. Clin. Oncol. 1998. Vol. 16. P. 897-906.

33. Jenkin D., Doyle J., Berry M. et al. Hodgkins disease in children: treatment with MOPP and low-dose, extended field irradiation without laparotomy: late results and toxicity // Med. Ped. Oncol. 1990. Vol. 18. P. 265-272.

34. Johnson P.W., Radford J.A., Cullen M.H. et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkins lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519) // J. Clin. Oncol. 2005. Vol. 23. P. 9208-9218.

35. Landman-Parker J., Pacquement H., Leblanc T. et al. Localized childhood Hodgkins disease: response-adapted chemotherapy with Etoposide, Bleomycin, Vinblastine, and Prednisone before low-dose radiation therapy results of the French Society of Pediatric Oncology Study MDH90.//J.Clin.Oncol.- 2000. Vol. 18. No. 7.- P.1500-1507.

36. Leiw K.H. Ding J.C., Cruickshank D. et al. Prognostic factors in patients with subdiaphragmatic Hodgkins disease // Hematol. Oncol. 1983. Vol. 1. P. 205-214.

37. Lobo-Sanahuya F., Garsia I., Barrantes J. Pediatric Hodgkins disease in Costa Rica: twelve years experience of primary treatment by chemotherapy alone, without laparotomy // Med. Pediatr. Oncol. 1994. Vol. 22. P. 398-403.

38. Mauch P., Goodman R., Rosenthal D.S. et al. An evaluation of total nodal irradiation as treatment for stage IIIA Hodgkins disease // Cancer. 1979. Vol. 43. P. 1255-1261.

39. Minot G.R. and Isaacs R. Lymphoblastoma (malignant lymphoma); age and sex incidence, duration of disease, and the effects of roentgen-ray and radium irradiation and surgery // J. A. M. A. 1926. Vol. 86. P. 1185-1189.

40. Mintz U., Miller J.B., Golomb H.M. et al. Pathologic stage I and II Hodgkins disease // Cancer. 1979. Vol. 44. P.1101.

41. Nachman J.B., Sposto R., Herzog P. et al. Randomized comparison of low-dose involvedfield radiotherapy and no radiotherapy for children with Hodgkin's disease who achieved a complete response to chemotherapy. // J. Clin. Oncol. - 2002. - Vol. 20. - 18. - P. 3765- 3771.

42. Nissen N.I., Nordentoft A.M. Radiotherapy versus combined modality treatment of stage I and II Hodgkins disease // Cancer/ Treatm. Repts. 1982. Vol. 66. P. 799-803.

43. Oberlin O., Lewerger G., Paquement H. et. al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkins disease. The experience of the French Society of Pediatric Oncology // J. Clin. Oncol. 1992. Vol. 10. No. 10. P. 1602 1608.

44. Pusey W.A. Cases of sarcoma and of Hodgkins disease treated by exposures to X-rays: a preliminary report // JAMA. 1902. Vol. 38. P. 166-169.

45. Reed D.M. On the pathological changes in Hodgkins disease, with especial reference to its relation to tuberculosis // Johns Hopkins Hosp. Rep. 1902. Vol. 10. P. 133-196.

46. Rodgers R.W., Fuller L.M., Hagemeister F.B. et al. Reassessment of prognostic factors in stage IIIA and IIIB Hodgkins disease treated with MOPP and radiotherapy // Cancer. 1981. Vol. 47. P. 2196-2203.

47. Sackmann-Muriel F., Zubizarreta P., Gallo G. et al. Hodgkins disease in children: results of a prospective randomized trial in a single institute in Argentina // Med. Pediatr. Oncol. 1997. Vol. 29. P. 544-552.

48. Schellong G. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. // Ann. Oncol. - 1996. - Vol. 7. - 4. - P. 67-72.

49. Schellong G., Brämswig J.H., Hörnig-Franz I. Treatment of children with Hodgkin's disease - results of the German Pediatric Oncology Group. // Ann. Oncol. - 1992. - Vol. 3. - 4. - P. 73-76.

50. Schellong G., Brämswing J., Hörning-Franz I. Hodgkins disease in children: combined modality treatment for stages IA, IB and IIA // Ann. Oncol. 1994. Vol. 5 (Suppl. 2). P. 113-115.

51. Schellong G., Hornig-Franz I., Riepenhausen M. et al. Hodgkins disease Stage IV Study (SIOP-HD-IV/87) // SIOP News. 1993. No. 7. P. 5.

52. Shankar A.G., Ashley S., Atra A. et al. A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkins disease // Eur. J. Cancer. 1998. Vol. 34. No. 13. P. 2058-2063.

53. Shankar A.G., Ashley S., Radford N. et al. Does histology influence outcome in childhood Hodgkins disease? Results from the United Kingdom Childrens Cancer Study Group // J. Clin. Oncol. 1997. Vol. 15. No. 7. P. 2622-2630.

54. Shimkin M.B., Opperman K.C., Bostick W.L. and Low-Beer B.V.A. Hodgkins disease: an analysis of frequency distribution and mortality at the University of California Hospital, 1914-1951 // Ann. Int. Med. 1955. Vol. 42. P. 136-153.

55. Slaughter D.P. and Craver L.F. Hodgkins disease; 5 year survival rate; value of early surgical treatment; notes on 4 cases of long duration // Am. J. Roentgenol. 1942. Vol. 47. P. 596-606.

56. Sripada S.S., Tenali S.G., Vasudevan M., Viswanadhan S. Hybrid (COPP/ABV) therapy in childhood Hodgkins disease: a study of 53 cases during 1989-1993 at the Cancer Institute, Madras // Pediatr. Hemanol. Oncol. 1995. Vol. 12. P. 333-341.

57. Sternberg C. Uber eine eigenartige unter dem bilde der pseudoleukemie verlaufende tuberkulose des lymphatischen apparates // Z. Heilk. 1898. Bd. 19. S. 21-90.

58. Teillet F., Delbrück H., Bayle-Weisgerber Ch. Et al. Möglichkeiten einer therapiereduction beim morbus Hodgkin. II. Ermöglicht eine primäre polychemotherapie der verzicht auf eine exlorative splenektomie bei klinisch lokalisiertem krankheitsbefall? // Dtsch. Med. Wochenschr. 1979. Bd. 104. S. 1405-1409.

59. Van den Berg H., Stuve W., Behrendt H. Treatment of Hodgkins disease in children with alternating mechlorethemine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy // Med. Pediatr. Oncol. 1997. Vol. 29. P. 23-27.

60. Weiner M.A., Leventhal B., Brecher M.L. et al. Randomized study of intensive MOPPABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkins disease in pediatric patients: a Pediatric Oncology Group Study // J. Clin. Oncol. 1997. Vol. 15. No. 8. P. 2769-2779.

61. Wiernik P.H., Gustafson J., Schimpff S.C. et al. Combined modality treatment of Hodgkins disease confined to lymph nodes. Results eight years later // Am. J. Med. 1979. Vol. 67. P. 183-193.